First Author: M.Baragheeth KUWAIT
Back to previous
To evaluate the efficacy of intraviteal Avastin® injection as monotherapy for submacular haemorrhage (SMH) secondary to neovascular age-related macular degeneration (n-AMD).
New Mowasat Hospital, Kuwait
A total of 24 treatment-naive patients (30 eyes) with SMH, involving the fovea, secondary to n-AMD were included. All patients were treated with an initial series of 3 consecutive monthly intravitreal Avastin® injections, followed by as-needed injections. Measurements of best-corrected visual acuity (BCVA), central foveal thickness (CFT), and area of SMH at diagnosis, as well as at 3, 6 and 12 months after treatment initiation were analyzed.
Over the course of 12 months follow-up, an average of 5.2 ± 1.7 Avastin® injections were administered. Recurrent haemorrhage was noted in 9 eyes (30%). Twelve months after treatment, the mean BCVA significantly improved from 1.12±0.56 LogMAR (logarithm of the minimum angle of resolution) to 0.58±0.78 LogMAR (P< 0.001). Eighteen eyes (60%) showed improvement of more than three lines of BCVA at 12 months after treatment. The CFT significantly decreased from 650.8 ± 184.3 µm at baseline to 312.9 ± 140.6 µm at 6 months (p < 0.001). The area of SMH significantly decreased from 9.5 ± 6.2 mm2 at baseline to 1.5 ± 6.9 mm2 at 6 months (p < 0.001). The change in CFT, and area of SMH were significantly correlated with the improvement in visual acuity 12 months after treatment.
Intravitreal Avastin® injection is an effective treatment option for patients with SMH secondary to n-AMD.